Europe
Experts from Peli BioThermal to share knowledge and industry insight at leading clinical trial conference
LGC, Biosearch Technologies proudly introduces RapiDxFire™ Thermostable RT, a truly thermostable reverse transcriptase designed specifically to meet the needs of diagnostic kit developers.
SOTIO, a biotechnology company owned by the PPF Group, announces that final data from the SOV02 Clinical Trial with DCVAC/OvCa will be presented in the plenary session as an oral presentation at the 2019 SGO’s 50th Annual Meeting on Women’s Cancer.
The University of Manchester, and Owlstone Medical announce the award of an Asthma UK/Innovate UK grant for theimprovement of asthma diagnosis.
Apogenix announced today that it will present an overview of its HERA-ligand technology platform for cancer immunotherapy at Cambridge Healthtech Institute’s 4thAnnual Cancer Immunotherapy: Executive Summit
Forendo Pharma today announces that it has successfully completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis.
Karolinska Development’s portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis.
Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and cachexia
Full year revenues from product sales were up over 51% on 2017 to €134.3 million, reflecting strong growth in both the USA and Europe. Including deferred license income, total revenues were €135.1 million (US$159.7 million) – an increase of almost 51% on 2017
Annual General Meeting to take place on 18 April 2019 in Basel
PRESS RELEASES